Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


The Fertility Show


 

Promise of blood test to predict course of Huntington's disease

12 June 2017

By Lea Goetz

Appeared in BioNews 904

Scientists have identified the first promising biomarker for Huntington's disease (HD) that could be harnessed in a simple blood test to predict disease onset and progression.

The blood test would measure levels of neurofilament, a protein released by damaged brain cells. The researchers found neurofilament levels increase as HD progresses, but can also be detected in the blood years before symptoms manifest.

'We have been trying to identify blood biomarkers to help track the progression of HD for well over a decade, and this is the best candidate that we have seen so far,' said senior author Dr Edward Wild at University College London (UCL), UK. 'Neurofilament has the potential to serve as a speedometer in Huntington's disease, since a single blood test reflects how quickly the brain is changing.'

Huntington's disease is an incurable, autosomal dominant genetic disease where patients suffer from a progressive decline of motor and cognitive function, including involuntary movements, personality changes and worsening dementia. The disease is caused by a mutation in the huntingtin gene, which causes brain cell death. Most HD carriers start to show symptoms in their 30s to 50s.

Previous research had linked concentration of neurofilament in the blood of patients with other neurodegenerative disorders, but until now neurofilament had only been measured in the cerebrospinal fluid of HD patients.

The researchers used data from the international TRACK-HD study, which gathered data using blood tests, brain scans and tests of cognitive and motor skills from 366 HD carriers and control volunteers over three years.

By comparing 201 HD carriers with 100 controls, the researchers found patients with the HD mutation had as much as three to six times higher levels of neurofilament in their blood compared with controls. Neurofilament could also be detected in HD carriers who were years away from showing symptoms.

'This is the first time neurofilament has been measured in blood, so much more work is needed to understand the potential and limitations of this test,' said lead author Lauren Byrne from UCL's Institute of Neurology. 'In the future, if drugs to slow HD become available, it may well be used to guide treatment decisions. For now, this test is most promising as a much-needed tool to help us design and run clinical trials of new drugs.'

The authors believe neurofilament may also have potential as a biomarker in the preclinical phases of other neurodegenerative diseases.

About 12 in 100,000 people in the UK are affected by HD and children have a 50 percent chance of inheriting the disorder. Gene tests, age and measures of brain volume have been the best predictors of HD until now.

The study was published in the Lancet Neurology.

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

26 June 2017 - by Meghna Kataria 
Eliminating the faulty protein that causes Huntingdon's disease goes some way to reversing disease progression in mice, a study has found...

22 May 2017 - by Jennifer Willows 
A woman whose father has Huntington’s disease has won the right to sue his doctors for negligence, for failing to tell her...
03 August 2015 - by Dr Victoria Burchell 
A genome-wide study of over 4000 people with Huntington's disease has identified the location several new gene variants that influence the onset of disease symptoms...
25 June 2012 - by Holly Rogers 
A single dose of an 'antisense' drug has been shown to slow, or even partially reverse, Huntington's disease in animal studies, according to a study published in Neuron....
05 July 2010 - by Dr Jay Stone 
Two papers published in the Lancet have suggested that the number of people in the UK suffering with Huntington’s disease (HD) may be double original figures and that patients are failing to be diagnosed due to the stigma attached to the illness...
07 September 2009 - by Ailsa Stevens 
Clinicians should be cautious about offering genetic testing to patients at risk from Huntington's disease to enable them to participate in clinical trials, Dr Sheila Simpson, a Clinical Geneticist at NHS Grampian Hospital, said in a talk at the annual conference of the British Society of Human Genetics at Warwick University....

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Moving the Boundaries of Human Reproduction

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Jacques Cohen

Dr Anna Smajdor

Dr Andy Greenfield

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation